Population pharmacokinetics and pharmacodynamics of two dosing regimens of antenatal corticosteroids: protocol for a prospective nested study in a randomised controlled trial
Introduction Antenatal corticosteroid (ACS) regimens have remained unchanged since the initial trials in 1972, with the optimal regimen still undetermined. The WHO ACTION (Antenatal CorticosTeroids for Improving Outcomes in preterm Newborns)-III trial is a three-arm individually randomised double-bl...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2025-06-01
|
| Series: | BMJ Open |
| Online Access: | https://bmjopen.bmj.com/content/15/6/e096523.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850137500025094144 |
|---|---|
| author | Adejumoke Idowu Ayede Olufemi T Oladapo Rekha Bharti Nitya Wadhwa Tina Lavin Nicole Minckas Ebunoluwa A Adejuyigbe Shivaprasad S Goudar William Jusko Shuchita Gupta Ayesha De Costa Adesina Olubukola Adeponle Ramana Moorthy Aripaka Francis Olubanji Awoniyi Nurudeen Ola Bello Anjali Dabral Zubair Hasan Dennis Anthony Isah Ranjit P Kangle Wojciech Krzyzanski Olatunji Okikiola Lawal Elijah-David Ukpahiu-Ojo Ogwu Kabir Olatunde Oyeniyi Amaresh P Patil Yeshita V Pujar Subramanian Ramachandran Sunil Ranga Ezekiel Onoja Ray Suresh Sivasankaran Manjunath S Somannavar Jyotsna Suri |
| author_facet | Adejumoke Idowu Ayede Olufemi T Oladapo Rekha Bharti Nitya Wadhwa Tina Lavin Nicole Minckas Ebunoluwa A Adejuyigbe Shivaprasad S Goudar William Jusko Shuchita Gupta Ayesha De Costa Adesina Olubukola Adeponle Ramana Moorthy Aripaka Francis Olubanji Awoniyi Nurudeen Ola Bello Anjali Dabral Zubair Hasan Dennis Anthony Isah Ranjit P Kangle Wojciech Krzyzanski Olatunji Okikiola Lawal Elijah-David Ukpahiu-Ojo Ogwu Kabir Olatunde Oyeniyi Amaresh P Patil Yeshita V Pujar Subramanian Ramachandran Sunil Ranga Ezekiel Onoja Ray Suresh Sivasankaran Manjunath S Somannavar Jyotsna Suri |
| collection | DOAJ |
| description | Introduction Antenatal corticosteroid (ACS) regimens have remained unchanged since the initial trials in 1972, with the optimal regimen still undetermined. The WHO ACTION (Antenatal CorticosTeroids for Improving Outcomes in preterm Newborns)-III trial is a three-arm individually randomised double-blind trial evaluating the efficacy and safety of two different ACS dosing regimens (currently used and lower-dose ACS regimens vs placebo) in women with a high probability of having a late preterm birth. This study protocol nested within this trial aims to evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) effects of two different ACS dosing regimens in pregnant women in the late preterm period (34–36 weeks) to help inform an optimal dosing regimen.Methods and analysis The study will be conducted in two of the five countries participating in the WHO ACTION-III trial—India (Delhi, Belagavi) and Nigeria (Ibadan and Ile-Ife). We will use a population PK approach using sparse sampling to study the PK effects of the two ACS regimens, that is, 6 mg dexamethasone phosphate (DEXp) or 2 mg betamethasone phosphate (BETp), administered intramuscularly every 12 hours for a maximum of four doses or till birth, whichever is earlier, compared with placebo. We will also ascertain the fetal–maternal ratio of DEXp and BETp at birth.Maternal venous blood samples will be collected at 0, 1–4 hours, 8–12 hours after the first dose, and at 24–36 hours, 48–60 hours, 72–96 hours after the last dose, and immediately after birth, along with cord blood. Concentrations of DEXp and BETp will be measured at set time points using a validated liquid chromatography mass spectroscopy assay. PD parameters measured will include total and differential white blood cell count (by automated analysers using electrical impedance), plasma glucose (hexokinase method) and serum cortisol (using a validated electrochemiluminescence immunoassay), at predefined time points. PK models will be developed for each drug using non-linear mixed effects methods. Optimal dosing will be investigated using Monte Carlo simulations.Ethics and dissemination The study has been approved by the WHO Ethics Review Committee and the site-specific ethics committees of the participating leading institutions. Written informed consent will be obtained from all participants. The study results will be published in a peer-reviewed journal and presented at scientific conferences.Trial registration number ISRCTN11434567. |
| format | Article |
| id | doaj-art-7c503a7c66fa424eb0ca4d6b4b6ca318 |
| institution | OA Journals |
| issn | 2044-6055 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | BMJ Open |
| spelling | doaj-art-7c503a7c66fa424eb0ca4d6b4b6ca3182025-08-20T02:30:50ZengBMJ Publishing GroupBMJ Open2044-60552025-06-0115610.1136/bmjopen-2024-096523Population pharmacokinetics and pharmacodynamics of two dosing regimens of antenatal corticosteroids: protocol for a prospective nested study in a randomised controlled trial Adejumoke Idowu AyedeOlufemi T OladapoRekha BhartiNitya WadhwaTina LavinNicole MinckasEbunoluwa A AdejuyigbeShivaprasad S GoudarWilliam JuskoShuchita GuptaAyesha De CostaAdesina Olubukola AdeponleRamana Moorthy AripakaFrancis Olubanji AwoniyiNurudeen Ola BelloAnjali DabralZubair HasanDennis Anthony IsahRanjit P KangleWojciech KrzyzanskiOlatunji Okikiola LawalElijah-David Ukpahiu-Ojo OgwuKabir Olatunde OyeniyiAmaresh P PatilYeshita V PujarSubramanian RamachandranSunil RangaEzekiel Onoja RaySuresh SivasankaranManjunath S SomannavarJyotsna SuriIntroduction Antenatal corticosteroid (ACS) regimens have remained unchanged since the initial trials in 1972, with the optimal regimen still undetermined. The WHO ACTION (Antenatal CorticosTeroids for Improving Outcomes in preterm Newborns)-III trial is a three-arm individually randomised double-blind trial evaluating the efficacy and safety of two different ACS dosing regimens (currently used and lower-dose ACS regimens vs placebo) in women with a high probability of having a late preterm birth. This study protocol nested within this trial aims to evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) effects of two different ACS dosing regimens in pregnant women in the late preterm period (34–36 weeks) to help inform an optimal dosing regimen.Methods and analysis The study will be conducted in two of the five countries participating in the WHO ACTION-III trial—India (Delhi, Belagavi) and Nigeria (Ibadan and Ile-Ife). We will use a population PK approach using sparse sampling to study the PK effects of the two ACS regimens, that is, 6 mg dexamethasone phosphate (DEXp) or 2 mg betamethasone phosphate (BETp), administered intramuscularly every 12 hours for a maximum of four doses or till birth, whichever is earlier, compared with placebo. We will also ascertain the fetal–maternal ratio of DEXp and BETp at birth.Maternal venous blood samples will be collected at 0, 1–4 hours, 8–12 hours after the first dose, and at 24–36 hours, 48–60 hours, 72–96 hours after the last dose, and immediately after birth, along with cord blood. Concentrations of DEXp and BETp will be measured at set time points using a validated liquid chromatography mass spectroscopy assay. PD parameters measured will include total and differential white blood cell count (by automated analysers using electrical impedance), plasma glucose (hexokinase method) and serum cortisol (using a validated electrochemiluminescence immunoassay), at predefined time points. PK models will be developed for each drug using non-linear mixed effects methods. Optimal dosing will be investigated using Monte Carlo simulations.Ethics and dissemination The study has been approved by the WHO Ethics Review Committee and the site-specific ethics committees of the participating leading institutions. Written informed consent will be obtained from all participants. The study results will be published in a peer-reviewed journal and presented at scientific conferences.Trial registration number ISRCTN11434567.https://bmjopen.bmj.com/content/15/6/e096523.full |
| spellingShingle | Adejumoke Idowu Ayede Olufemi T Oladapo Rekha Bharti Nitya Wadhwa Tina Lavin Nicole Minckas Ebunoluwa A Adejuyigbe Shivaprasad S Goudar William Jusko Shuchita Gupta Ayesha De Costa Adesina Olubukola Adeponle Ramana Moorthy Aripaka Francis Olubanji Awoniyi Nurudeen Ola Bello Anjali Dabral Zubair Hasan Dennis Anthony Isah Ranjit P Kangle Wojciech Krzyzanski Olatunji Okikiola Lawal Elijah-David Ukpahiu-Ojo Ogwu Kabir Olatunde Oyeniyi Amaresh P Patil Yeshita V Pujar Subramanian Ramachandran Sunil Ranga Ezekiel Onoja Ray Suresh Sivasankaran Manjunath S Somannavar Jyotsna Suri Population pharmacokinetics and pharmacodynamics of two dosing regimens of antenatal corticosteroids: protocol for a prospective nested study in a randomised controlled trial BMJ Open |
| title | Population pharmacokinetics and pharmacodynamics of two dosing regimens of antenatal corticosteroids: protocol for a prospective nested study in a randomised controlled trial |
| title_full | Population pharmacokinetics and pharmacodynamics of two dosing regimens of antenatal corticosteroids: protocol for a prospective nested study in a randomised controlled trial |
| title_fullStr | Population pharmacokinetics and pharmacodynamics of two dosing regimens of antenatal corticosteroids: protocol for a prospective nested study in a randomised controlled trial |
| title_full_unstemmed | Population pharmacokinetics and pharmacodynamics of two dosing regimens of antenatal corticosteroids: protocol for a prospective nested study in a randomised controlled trial |
| title_short | Population pharmacokinetics and pharmacodynamics of two dosing regimens of antenatal corticosteroids: protocol for a prospective nested study in a randomised controlled trial |
| title_sort | population pharmacokinetics and pharmacodynamics of two dosing regimens of antenatal corticosteroids protocol for a prospective nested study in a randomised controlled trial |
| url | https://bmjopen.bmj.com/content/15/6/e096523.full |
| work_keys_str_mv | AT populationpharmacokineticsandpharmacodynamicsoftwodosingregimensofantenatalcorticosteroidsprotocolforaprospectivenestedstudyinarandomisedcontrolledtrial AT adejumokeidowuayede populationpharmacokineticsandpharmacodynamicsoftwodosingregimensofantenatalcorticosteroidsprotocolforaprospectivenestedstudyinarandomisedcontrolledtrial AT olufemitoladapo populationpharmacokineticsandpharmacodynamicsoftwodosingregimensofantenatalcorticosteroidsprotocolforaprospectivenestedstudyinarandomisedcontrolledtrial AT rekhabharti populationpharmacokineticsandpharmacodynamicsoftwodosingregimensofantenatalcorticosteroidsprotocolforaprospectivenestedstudyinarandomisedcontrolledtrial AT nityawadhwa populationpharmacokineticsandpharmacodynamicsoftwodosingregimensofantenatalcorticosteroidsprotocolforaprospectivenestedstudyinarandomisedcontrolledtrial AT tinalavin populationpharmacokineticsandpharmacodynamicsoftwodosingregimensofantenatalcorticosteroidsprotocolforaprospectivenestedstudyinarandomisedcontrolledtrial AT nicoleminckas populationpharmacokineticsandpharmacodynamicsoftwodosingregimensofantenatalcorticosteroidsprotocolforaprospectivenestedstudyinarandomisedcontrolledtrial AT ebunoluwaaadejuyigbe populationpharmacokineticsandpharmacodynamicsoftwodosingregimensofantenatalcorticosteroidsprotocolforaprospectivenestedstudyinarandomisedcontrolledtrial AT shivaprasadsgoudar populationpharmacokineticsandpharmacodynamicsoftwodosingregimensofantenatalcorticosteroidsprotocolforaprospectivenestedstudyinarandomisedcontrolledtrial AT williamjusko populationpharmacokineticsandpharmacodynamicsoftwodosingregimensofantenatalcorticosteroidsprotocolforaprospectivenestedstudyinarandomisedcontrolledtrial AT shuchitagupta populationpharmacokineticsandpharmacodynamicsoftwodosingregimensofantenatalcorticosteroidsprotocolforaprospectivenestedstudyinarandomisedcontrolledtrial AT ayeshadecosta populationpharmacokineticsandpharmacodynamicsoftwodosingregimensofantenatalcorticosteroidsprotocolforaprospectivenestedstudyinarandomisedcontrolledtrial AT adesinaolubukolaadeponle populationpharmacokineticsandpharmacodynamicsoftwodosingregimensofantenatalcorticosteroidsprotocolforaprospectivenestedstudyinarandomisedcontrolledtrial AT ramanamoorthyaripaka populationpharmacokineticsandpharmacodynamicsoftwodosingregimensofantenatalcorticosteroidsprotocolforaprospectivenestedstudyinarandomisedcontrolledtrial AT francisolubanjiawoniyi populationpharmacokineticsandpharmacodynamicsoftwodosingregimensofantenatalcorticosteroidsprotocolforaprospectivenestedstudyinarandomisedcontrolledtrial AT nurudeenolabello populationpharmacokineticsandpharmacodynamicsoftwodosingregimensofantenatalcorticosteroidsprotocolforaprospectivenestedstudyinarandomisedcontrolledtrial AT anjalidabral populationpharmacokineticsandpharmacodynamicsoftwodosingregimensofantenatalcorticosteroidsprotocolforaprospectivenestedstudyinarandomisedcontrolledtrial AT zubairhasan populationpharmacokineticsandpharmacodynamicsoftwodosingregimensofantenatalcorticosteroidsprotocolforaprospectivenestedstudyinarandomisedcontrolledtrial AT dennisanthonyisah populationpharmacokineticsandpharmacodynamicsoftwodosingregimensofantenatalcorticosteroidsprotocolforaprospectivenestedstudyinarandomisedcontrolledtrial AT ranjitpkangle populationpharmacokineticsandpharmacodynamicsoftwodosingregimensofantenatalcorticosteroidsprotocolforaprospectivenestedstudyinarandomisedcontrolledtrial AT wojciechkrzyzanski populationpharmacokineticsandpharmacodynamicsoftwodosingregimensofantenatalcorticosteroidsprotocolforaprospectivenestedstudyinarandomisedcontrolledtrial AT olatunjiokikiolalawal populationpharmacokineticsandpharmacodynamicsoftwodosingregimensofantenatalcorticosteroidsprotocolforaprospectivenestedstudyinarandomisedcontrolledtrial AT elijahdavidukpahiuojoogwu populationpharmacokineticsandpharmacodynamicsoftwodosingregimensofantenatalcorticosteroidsprotocolforaprospectivenestedstudyinarandomisedcontrolledtrial AT kabirolatundeoyeniyi populationpharmacokineticsandpharmacodynamicsoftwodosingregimensofantenatalcorticosteroidsprotocolforaprospectivenestedstudyinarandomisedcontrolledtrial AT amareshppatil populationpharmacokineticsandpharmacodynamicsoftwodosingregimensofantenatalcorticosteroidsprotocolforaprospectivenestedstudyinarandomisedcontrolledtrial AT yeshitavpujar populationpharmacokineticsandpharmacodynamicsoftwodosingregimensofantenatalcorticosteroidsprotocolforaprospectivenestedstudyinarandomisedcontrolledtrial AT subramanianramachandran populationpharmacokineticsandpharmacodynamicsoftwodosingregimensofantenatalcorticosteroidsprotocolforaprospectivenestedstudyinarandomisedcontrolledtrial AT sunilranga populationpharmacokineticsandpharmacodynamicsoftwodosingregimensofantenatalcorticosteroidsprotocolforaprospectivenestedstudyinarandomisedcontrolledtrial AT ezekielonojaray populationpharmacokineticsandpharmacodynamicsoftwodosingregimensofantenatalcorticosteroidsprotocolforaprospectivenestedstudyinarandomisedcontrolledtrial AT sureshsivasankaran populationpharmacokineticsandpharmacodynamicsoftwodosingregimensofantenatalcorticosteroidsprotocolforaprospectivenestedstudyinarandomisedcontrolledtrial AT manjunathssomannavar populationpharmacokineticsandpharmacodynamicsoftwodosingregimensofantenatalcorticosteroidsprotocolforaprospectivenestedstudyinarandomisedcontrolledtrial AT jyotsnasuri populationpharmacokineticsandpharmacodynamicsoftwodosingregimensofantenatalcorticosteroidsprotocolforaprospectivenestedstudyinarandomisedcontrolledtrial |